Nektar Therapeutics: Investor and Analyst R&D Day (Nektar Therapeutics) - Oct 11, 2015 - “Results of Phase 2 EERW efficacy study”; “Most patients in the study were on background NSAIDs”; “During randomized phase, no placebo rebound and study did not meet primary endpoint”; “In the subset analysis of the 25 patients that did not take background NSAIDs, a rebound was observed in placebo patients”
P2 data • Pain
|